Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $7 to $9.
Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $7 to $9.